Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sotatercept for Anemia in ESRD on Hemodialysis
NCT01146574Phase 2Completed
- Sponsor
- Celgene Corporation
- Start
- Jun 2010
- Primary completion
- Mar 2016
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of sotatercept in anemia (5 arms), sponsored by Celgene Corporation. Primary endpoints: Observed Maximum Concentration at Day 28, Time to Maximum Concentration at Day 28 and 1 more. Started Jun 2010; status: completed.
02
Drugs
sotatercept
03
Conditions
anemia
Beyond the preview
Go deeper on NCT01146574.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01146574.